2023 年第 7 期 第 18 卷

卡格列净联合西格列汀在老年2型糖尿病患者中的应用效果研究

Application effect of canagliflozin combined with sitagliptin in elderly patients with type 2 diabetes mellitus

作者：姜爱凤1马立萍2马涵英2李亚冬2

英文作者：Jiang Aifeng1 Ma Liping2 Ma Hanying2 Li Yadong2

单位：1首都医科大学附属北京安贞医院第二门诊部，北京100029;2首都医科大学附属北京安贞医院全科医疗科，北京100029

英文单位：1Second Outpatient Department Beijing Anzhen Hospital Capital Medical University Beijing 100029 China; 2Department of General Medicine Beijing Anzhen Hospital Capital Medical University Beijing 100029 China

关键词：糖尿病；卡格列净；西格列汀；血糖；体质量；安全性

英文关键词：Diabetesmellitus;Canagliflozin;Sitagliptin;Bloodglucose;Bodymass;Safety

• 摘要：

• 目的  探究卡格列净联合西格列汀在老年2型糖尿病患者中的应用效果。方法  选取2020年1—12月在首都医科大学附属北京安贞医院接受治疗的132例老年2型糖尿病患者为研究对象，经随机数字表法分为对照组和观察组，各66例。对照组在饮食、运动等常规干预基础上采用二甲双胍治疗；观察组在对照组基础上采用卡格列净联合西格列汀治疗。比较2组血糖指标、空腹及餐后2 h C肽、尿微量白蛋白水平以及体质量、腰围、腹围、体重指数和不良反应。结果  治疗后，观察组空腹血糖、餐后2 h血糖、糖化血红蛋白［（5.9±0.8）%比（6.2±0.8）%］、空腹C肽、餐后2 h C肽、尿微量白蛋白水平低于对照组，差异均有统计学意义（均P＜0.05）。治疗后，观察组体质量［（62±6）kg比（65±6）kg］、腰围、腹围、体重指数低于对照组，差异均有统计学意义（均P＜0.05）。观察组不良反应发生率低于对照组［7.6%（5/66）比19.7%（13/66）］，差异有统计学意义（P＜0.05）。结论  卡格列净联合西格列汀对老年2型糖尿病患者进行治疗的效果显著，可有效控制患者血糖水平，降低尿微量白蛋白等相关指标，安全性较高。

• Objective  To explore the application effect of canagliflozin combined with sitagliptin in elderly patients with type 2 diabetes mellitus. Methods  A total of 132 elderly patients with type 2 diabetes mellitus who were treated in Beijing Anzhen Hospital, Capital Medical University from January to December 2020 were selected as the research objects. They were divided into the control group and the observation group according to the random number table method, with 66 cases in each group. The control group was treated with metformin on the basis of routine intervention such as diet and exercise. The observation group was treated with canagliflozin combined with sitagliptin on the basis of the control group. The blood glucose index, fasting and 2 h postprandial C-peptide, urinary microalbumin levels, body mass, waist circumference, abdominal circumference, body mass index and adverse reactions were compared between the two groups. Results  After treatment, the levels of fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin［(5.9±0.8)% vs (6.2±0.8)%］, fasting C-peptide, 2 h postprandial C-peptide and urinary microalbumin in the observation group were lower than those in the control group (all P<0.05). After treatment, the body mass［(62±6)kg vs (65±6)kg］, waist circumference, abdominal circumference and body mass index in the observation group were lower than those in the control group (all P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group ［7.6%（5/66） vs 19.7%（13/66）］(P<0.05). Conclusion  Canagliflozin combined with sitagliptin is effective in the treatment of elderly patients with type 2 diabetes mellitus, which can effectively control the blood glucose level of patients, reduce the urinary microalbumin and other related indicators, and has high safety.